Develop Proprietary Compounds

Galectin Therapeutics uses its knowledge of galectin proteins to study the effects of our propriety compounds in diseases with clinical needs. Our compounds bind to galectin proteins and disrupt their function, which has a beneficial effect on the disease states.

 

Picture3 Our drug candidate in development (GR-MD-02) was generated from naturally occurring carbohydrate polymers using proprietary chemistry. Currently in development, GR-MD-02 is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer that is comprised predominantly of galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. Structural studies have shown that GR-MD-02 binds to galectin-1 and to galectin-3 with binding affinity to galectin-3 > galectin-1. GR-MD-02 targets extracellular galectins. Click here to view our pipeline.

Learn about our development program and key data for GR-MD-02.

Read about our intellectual property protection for GR-MD-02.

GR-MD-02



Currently in development, GR-MD-02 is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer that is comprised predominantly of galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. Structural studies have shown that GR-MD-02 binds to galectin-1 (Miller 2009 Biochem J.pdf) and to galectin-3 (unpublished data) with binding affinity to galectin-3 > galectin-1. Similar to GM-CT-01, GR-MD-02 targets extracellular galectins.

Key features include:
  • IND (January 2013) active for use in patients with non-alcoholic steatohepatitis (NASH) with advanced fibrosis.

  • IND under development for use in metastatic melanoma in combination with Yervoy (ipilimumab, BMS).

  • Low toxicity potential because carbohydrates are metabolized to harmless compounds unlike other drugs that have toxic metabolites

  • API inexpensive to manufacture; abundant natural starting material

  • Compound for subcutaneous administration under development

Read about our intellectual property protection for GR-MD-02.